Medical bioremediation of age-related diseases

Jacques M. Mathieu, John Schloendorn, Bruce Rittmann, Pedro J J Alvarez

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.

Original languageEnglish (US)
Article number21
JournalMicrobial Cell Factories
Volume8
DOIs
StatePublished - Apr 9 2009

Fingerprint

Environmental Biodegradation
Bioremediation
Enzymes
Microbial Genetics
Macular Degeneration
Therapeutic Uses
Biodegradation
Organic compounds
Antibodies
Atherosclerosis
Alzheimer Disease
Homeostasis

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Medical bioremediation of age-related diseases. / Mathieu, Jacques M.; Schloendorn, John; Rittmann, Bruce; Alvarez, Pedro J J.

In: Microbial Cell Factories, Vol. 8, 21, 09.04.2009.

Research output: Contribution to journalArticle

Mathieu, Jacques M. ; Schloendorn, John ; Rittmann, Bruce ; Alvarez, Pedro J J. / Medical bioremediation of age-related diseases. In: Microbial Cell Factories. 2009 ; Vol. 8.
@article{5f464228c8314bb7aa485006960b0210,
title = "Medical bioremediation of age-related diseases",
abstract = "Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is {"}medical bioremediation,{"} the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.",
author = "Mathieu, {Jacques M.} and John Schloendorn and Bruce Rittmann and Alvarez, {Pedro J J}",
year = "2009",
month = "4",
day = "9",
doi = "10.1186/1475-2859-8-21",
language = "English (US)",
volume = "8",
journal = "Microbial Cell Factories",
issn = "1475-2859",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Medical bioremediation of age-related diseases

AU - Mathieu, Jacques M.

AU - Schloendorn, John

AU - Rittmann, Bruce

AU - Alvarez, Pedro J J

PY - 2009/4/9

Y1 - 2009/4/9

N2 - Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.

AB - Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.

UR - http://www.scopus.com/inward/record.url?scp=65149088269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65149088269&partnerID=8YFLogxK

U2 - 10.1186/1475-2859-8-21

DO - 10.1186/1475-2859-8-21

M3 - Article

C2 - 19358742

AN - SCOPUS:65149088269

VL - 8

JO - Microbial Cell Factories

JF - Microbial Cell Factories

SN - 1475-2859

M1 - 21

ER -